These effects were even more intense upon using exosomes derived from 0.1 ng/ml TGFβ-pretreated WJ-MSCs, suggesting that these pre-treated WJ-MSCs might significantly benefit the liver fibrosis patients (Salehipour Bavarsad et al., 2022). This evidence concerns the gene TGFB1 and Hepatic fibrosis.